APTAMER GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.675 GBX | 0.00% |
|
-25.00% | -41.30% |
| 04-22 | EARNINGS AND TRADING: Zenova's Kitemark award; Carnival's eyes savings | AN |
| 04-18 | Aptamer inks new Optimer+ transplant rejection therapy partnership | AN |
| Sales 2022 | 4.04M 5.06M 404M | Sales 2023 | 1.75M 2.2M 175M | Capitalization | 4.66M 5.85M 466M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -2.51M -200M | Net income 2023 | -7M -8.78M -700M | EV / Sales 2022 | 15.1 x |
| Net cash position 2022 | 5.38M 6.75M 538M | Net Debt 2023 | 844K 1.06M 84.4M | EV / Sales 2023 | 3.14 x |
| P/E ratio 2022 |
-29.6
x | P/E ratio 2023 |
-0.59
x | Employees | 37 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aptamer Group plc
| 1 week | -25.00% | ||
| Current month | -6.90% | ||
| 1 month | +28.57% | ||
| 3 months | -28.95% | ||
| 6 months | -50.00% | ||
| Current year | -41.30% |
1 week
0.65
0.83
1 month
0.500.90
Current year
0.451.40
1 year
0.4530.50
3 years
0.45157.00
5 years
0.45157.00
10 years
0.45157.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Bunka
FOU | Founder | - | 31/12/07 |
Arron Tolley
FOU | Founder | 46 | 31/12/07 |
Andrew Rapson
DFI | Director of Finance/CFO | - | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dean Fielding
BRD | Director/Board Member | 59 | 20/08/23 |
Arron Tolley
FOU | Founder | 46 | 31/12/07 |
David Bunka
FOU | Founder | - | 31/12/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 0.675 | 0.00% | 2,573,613 |
| 02/05/24 | 0.675 | 0.00% | 1,672,184 |
| 01/05/24 | 0.675 | -6.90% | 2,192,419 |
| 30/04/24 | 0.725 | -3.33% | 3,972,676 |
| 29/04/24 | 0.75 | -16.67% | 5,338,187 |
Delayed Quote London S.E., May 03, 2024 at 04:35 pm
More quotes
Aptamer Group plc is a developer of Optimer binders in the life sciences industry. It offers custom Optimer selection and development services. It delivers aptamer-based solutions to its customer bases for a range of therapeutic, diagnostic, and target-binding applications. It develops Optimer binders for therapeutics, diagnostics, bioprocessing, and research applications. The Optimer platform delivers aptamer tools that enables researchers and developers across the spectrum of the life sciences. Optimer binders has developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Optimer act as agonists, antagonists, or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease.
Calendar
14/10/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -41.30% | 3.96M | |
| +5.70% | 32.88B | |
| +18.46% | 7.84B | |
| +22.71% | 3.95B | |
| -17.95% | 3.11B | |
| -19.93% | 1.38B | |
| -30.65% | 1.21B | |
| +4.36% | 933M | |
| -34.81% | 911M | |
| -26.60% | 829M |
- Stock Market
- Equities
- APTA Stock
